Trials / Completed
CompletedNCT05733533
A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study of Efficacy and Safety of HRS-2261 in Refractory Chronic Cough
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 97 (actual)
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II study that will investigate the efficacy, safety and tolerability of HRS-2261 in subjects with refractory chronic cough using a double blind, placebo controlled, randomized study design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-2261 oral tablet | HRS-2261 oral tablet, oral, BID |
| DRUG | Matching placebo to HRS-2261 | Matching placebo to HRS-2261, oral, BID |
Timeline
- Start date
- 2023-03-09
- Primary completion
- 2024-03-05
- Completion
- 2024-03-05
- First posted
- 2023-02-17
- Last updated
- 2026-01-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05733533. Inclusion in this directory is not an endorsement.